14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
EW vs RBOT.WS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
EW Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)
EW Overall Winner
6-Pillar Tally: EW 6 – 0 RBOT.WS
Matrix Metrics: EW 9 – 1 RBOT.WS
As of Nov 20, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EW carries a Unified Composite Score of 40.0/100 (SELL) at $101.85 (30.1x Forward P/E, 28.8% operating margin), whereas RBOT.WS carries 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. EW 40.0/100 SELL), EW captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (28.8% vs. N/A operating margin) and revenue trajectory (+10.5% vs. N/A YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EW vs RBOT.WS. Trailing 12-month operating profitability (EW 28.8% vs RBOT.WS N/A) and valuation multiples (EW 30.1x vs RBOT.WS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Orthopedic, Prosthetic & Surgical Appliances & Supplies value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ EW vs RBOT.WS Key Questions & Quantitative Answers
As of Nov 20, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EW carries a Unified Composite Score of 40.0/100 (SELL) at $101.85 (30.1x Forward P/E, 28.8% operating margin), whereas RBOT.WS carries 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. EW 40.0/100 SELL), EW captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (28.8% vs. N/A operating margin) and revenue trajectory (+10.5% vs. N/A YoY).
EW leads the Growth & Scale pillar: EW posts +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin), compared with RBOT.WS at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, EW generates $6.67B in USD-normalized revenue versus N/A for RBOT.WS. In operating R&D and SG&A reinvestment, EW deploys 49.2% of Rev ($3.28B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RBOT.WS.
EW screens cheaper on headline valuation multiples. EW trades at 30.1x Forward P/E, 60.4x Trailing P/E, 2.32x PEG, and 8.6x EV/Revenue (21.3% FCF margin), whereas RBOT.WS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EW (9.3% ROE) versus RBOT.WS (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, EW carries 173.0% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.43β · 27% Vol realized risk). By comparison, RBOT.WS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00 (RBOT.WS) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.